COVID-19: Immunology and treatment options

dc.creatorFelsenstein, Susanna
dc.creatorHerbert, Jenny A.
dc.creatorMcNamara, Paul S.
dc.creatorHedrich, Christian M.
dc.date2020-09-17T13:10:36Z
dc.date2020-09-17T13:10:36Z
dc.date2020-06
dc.date.accessioned2023-09-28T20:06:57Z
dc.date.available2023-09-28T20:06:57Z
dc.identifierFELSENSTEIN, S. et al. COVID-19: Immunology and treatment options. Clinical Immunology, [S.l.], v. 215, June 2020.
dc.identifierhttps://www.sciencedirect.com/science/article/pii/S1521661620303181
dc.identifierhttp://repositorio.ufla.br/jspui/handle/1/43114
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9044820
dc.descriptionThe novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As protective immunity does not exist in humans and the virus is capable of escaping innate immune responses, it can proliferate, unhindered, in primarily infected tissues. Subsequent cell death results in the release of virus particles and intracellular components to the extracellular space, which result in immune cell recruitment, the generation of immune complexes and associated damage. Infection of monocytes/macrophages and/or recruitment of uninfected immune cells can result in massive inflammatory responses later in the disease. Uncontrolled production of pro-inflammatory mediators contributes to ARDS and cytokine storm syndrome. Antiviral agents and immune modulating treatments are currently being trialled. Understanding immune evasion strategies of SARS-CoV2 and the resulting delayed massive immune response will result in the identification of biomarkers that predict outcomes as well as phenotype and disease stage specific treatments that will likely include both antiviral and immune modulating agents.
dc.languageen_US
dc.publisherElsevier
dc.rightsrestrictAccess
dc.sourceClinical Immunology
dc.subjectCOVID-19
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
dc.subjectImmunology
dc.subjectImmune modulating treatment
dc.subjectAcute Respiratory Distress Syndrome (ARDS)
dc.subjectCytokine storm syndrome
dc.titleCOVID-19: Immunology and treatment options
dc.typeArtigo


Este ítem pertenece a la siguiente institución